《Informa Pharma Intelligence：2022美国、欧洲和新兴医药市场准入趋势白皮书（英文版）（28页）.pdf》由会员分享，可在线阅读，更多相关《Informa Pharma Intelligence：2022美国、欧洲和新兴医药市场准入趋势白皮书（英文版）（28页）.pdf（28页珍藏版）》请在三个皮匠报告上搜索。

1、Market Access Trends in the US,Europe,and Emerging MarketsDatamonitor HealthcarePharma intelligence|2/March 2019 Informa UK Ltd 2019(Unauthorized photocopying prohibited.)Rising drug spending and increased desire for expenditure controls are consistent themes across the US,Europe,and emerging market

2、s.With governments and private healthcare systems under increasing pressure to fund high-cost,innovative therapies,which often launch with limited clinical trial evidence,payers are looking towards new and enhanced reimbursement processes which align drug funding with patient value.Based on these gr

3、owing demands,the healthcare policy environment remains fluid,with payers introducing increasingly restrictive cost-control mechanisms in order to limit the burden on constrained healthcare budgets.For pharmaceutical manufacturers,success will require increasing flexibility on price and the ability

4、to adapt to new access scenarios brought about by changing access dynamics and geographical differences.Pricing pressures are present in all surveyed markets,with payers either looking to introduce new mechanisms or enhance existing ones to control healthcare spending.While the majority of European

5、markets have existing processes to control drug prices,national healthcare authorities are continually looking to sharpen these tools in response to changing market dynamics.In contrast,with a fragmented healthcare system and lack of formal health technology assessment process,mechanisms for price c

6、ontrol are relatively absent in the US.However,with rising drug spending and high out-of-pocket costs,public appetite for action on prescription drug prices is strong,resulting in a proliferation of new healthcare policies,growing demand for value-based pricing,and increased transparency within the